This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: Q96.3 | Special Copayment Reduction: V021 | Re-certification cycle: 5 years |
| B. Synonyms | None |
| C. Adult onset | First presentation in adulthood possible — because the mosaic form has a mild phenotype, it is sometimes not diagnosed in childhood and is found in adulthood during evaluation for primary amenorrhea or infertility. |
| 1. History | First described by Turner in 1938 → 45,X karyotype confirmed by Ford et al. in 1959 → mosaic forms described in the 1960s → active research on phenotype-genotype associations today. |
| 2. Causes | Nondisjunction or anaphase lag of the X (or Y) chromosome during early mitosis after fertilization leads to a mixture of two cell lines. Unrelated to parental age. |
| 3. Genetics | 45,X / 46,XX or 45,X / 46,XY. The proportion of the 46,XY cell line determines the degree of external genital abnormality and gonadal dysgenesis. SHOX haploinsufficiency → short stature. |
| 4. Epidemiology | Turner syndrome overall: 1 in 2,500 live-born girls. The mosaic form (Q96.3) is about 15–25% of all Turner syndrome. |
| 5. Pathophysiology | The proportion of 45,X cells and the tissues in which they are distributed determine ovarian function and the degree of cardiovascular and renal abnormalities. The higher the proportion of the normal cell line, the milder the phenotype. |
| 6. Symptoms | Short stature (mild), primary/secondary amenorrhea, premature ovarian insufficiency. Classic Turner features such as webbed neck and lymphedema are less frequent. |
| 7. Signs | Bicuspid aortic valve, horseshoe kidney, autoimmune thyroiditis. 45,X/46,XY type: increased risk of gonadoblastoma. |
| 8. Screening | Prenatal cfDNA, fetal ultrasound. Karyotype analysis for growth delay or delayed puberty in childhood. Found during evaluation for POI in adults. |
| 9. Diagnosis | Peripheral blood karyotype analysis (at least 30 cells). Detection of low-level mosaicism by FISH and SNP array. Confirmation of Y-specific sequences by PCR. |
| 10. Treatment | Growth hormone therapy, estrogen replacement (pubertal induction, bone density). 45,X/46,XY type: prophylactic gonadectomy. Cardiovascular and renal follow-up. |
| 11. Prognosis | Better than the classic form. Spontaneous pregnancy possible in some. Long-term monitoring for cardiovascular complications is essential. |
| 12. Prevention | Genetic counseling, prenatal diagnosis (cfDNA, amniotic fluid). Preventive management of gonadoblastoma in the 45,X/46,XY type. Multidisciplinary follow-up. |
| 13. References | 10 references (PMID / DOI) |
The history of Turner syndrome begins with a 1938 paper in which the American endocrinologist Henry H. Turner first described seven female patients characterized by sexual infantilism, webbed neck and cubitus valgus. At the time, pituitary dysfunction was presumed to be the cause. In 1959, Ford et al. confirmed the 45,X karyotype in patients with this syndrome, identifying it as the first human sex chromosome aneuploidy disorder.
With the development of cytogenetic techniques in the 1960s, the existence of mosaic forms in which two or more cell lines coexist, in addition to simple 45,X, became known. It was observed that the 45,X/46,XX mosaic form has a markedly milder phenotype than the classic form, so many cases are not diagnosed until adulthood. In the 1960s–1970s, the 45,X/46,XY mosaic form was shown to be associated with gonadal dysgenesis and a risk of gonadoblastoma.
Since the 1990s, the introduction of fluorescence in situ hybridization (FISH) and array comparative genomic hybridization (array CGH) has made it possible to detect low-level mosaicism that could not be found by G-banding. In the 2000s, single nucleotide polymorphism (SNP) arrays and next-generation sequencing (NGS) have been used for even more precise diagnosis. The 2006 Chicago international consensus statement incorporated the 45,X/46,XY type into the DSD classification system as "mixed gonadal dysgenesis."
Recently, early oocyte cryopreservation and the use of assisted reproductive technology by women with mosaic Turner syndrome have been actively discussed, and with reports of spontaneous pregnancy in some 45,X/46,XX women, the paradigm of reproductive counseling has changed. Guidelines on growth hormone, estrogen replacement and cardiovascular follow-up have been continuously revised based on decades of clinical experience.
Q96.3 mosaic Turner syndrome results from errors occurring during early mitosis of the zygote or embryo and is pathogenetically distinct from classic 45,X, which originates at the meiotic stage. The core mechanism is chromosomal nondisjunction or anaphase lag during cell division, by which two or more cell lines form from a single zygote.
In the 45,X/46,XX mosaic form, the most common route is that one X chromosome is lost by anaphase lag during mitosis in an initial 46,XX zygote, producing 45,X cells. Conversely, starting from a 45,X zygote, 46,XX cells may be produced by X chromosome nondisjunction, in which case a 47,XXX cell line may also be present. In the 45,X/46,XY mosaic form, the most common route is the generation of 45,X cells by Y chromosome anaphase lag in a 46,XY zygote.
The timing of the error has an important effect on the phenotype. The earlier in embryonic division the error occurs, the higher the proportion of 45,X cells and the closer the phenotype to the classic form; the later the error occurs, the higher the proportion of the normal cell line and the milder the phenotype. In addition, the expression of ovarian function, cardiac malformations and renal abnormalities differs depending on which tissues the 45,X cells are concentrated in. Because of the sporadic nature of mitotic errors, the condition is unrelated to parental age and the recurrence rate within families is very low.
Because parental karyotypes are usually normal, mosaic Turner syndrome is not a recurrent familial disease. However, considering the rare possibility of low-level germline mosaicism in one parent, confirmation of parental karyotypes is sometimes recommended during genetic counseling.
The karyotypes of Q96.3 fall into two main types. 45,X/46,XX has a female sex chromosome constitution in both cell lines, and 45,X/46,XY is a mixture of a normal male karyotype and a 45,X cell line. Distinguishing the two types is important because their clinical courses and risks differ.
In the 45,X/46,XX mosaic form, the higher the proportion of the 46,XX cell line, the better ovarian function is preserved and the milder the physical features. In some patients, spontaneous pubertal progression and spontaneous pregnancy are possible. Clinically, however, it is important that the cell line proportions in peripheral blood do not necessarily match those in ovarian tissue, so reproductive function is difficult to predict from blood results alone.
The 45,X/46,XY mosaic form is handled in the context of disorders of sex development (DSD). Because of the presence of the Y chromosome-specific GBY region (gonadoblastoma locus on Y chromosome), the risk of gonadoblastoma and dysgerminoma is increased. The phenotype varies, with external genitalia ranging from female to male and ambiguous, and is determined by the proportion of Y-containing cells in each tissue.
Molecular genetically, the main cause of short stature in Turner syndrome is haploinsufficiency of the SHOX gene (Xp22.33, PAR1 region). Deletion of the short arm of X (Xp-) is associated with Turner physical features, and deletion of the long arm of X (Xq-) with ovarian failure. Recently, research using SNP array analysis to determine the maternal or paternal origin of the remaining X chromosome and the presence of microdeletions and duplications has been actively under way. TIMP1, ZFX and others have been reported to be involved in maintaining ovarian function.
Turner syndrome occurs in about 1 in 2,500 live-born girls and is one of the most common sex chromosome aneuploidies; worldwide, more than about 1 million people are estimated to have received this diagnosis. In natural pregnancies, about 99% of fetuses with Turner syndrome are spontaneously miscarried, accounting for about 10% of all spontaneous miscarriages.
The mosaic form (Q96.3, 45,X/46,XX or 45,X/46,XY) accounts for about 15–25% of all Turner syndrome. However, the figure varies with the karyotyping method used and the number of cells counted, and when highly sensitive techniques such as FISH or SNP arrays are used, low-level mosaicism is sometimes found even in cases previously classified as simple 45,X.
The 45,X/46,XY mosaic form is reported at about 5–10% of all Turner syndrome in phenotypic females, and at about 15% of patients attending DSD clinics in phenotypic males or those with ambiguous external genitalia. Racial differences in incidence are not clear, but the diagnosis rate varies greatly between regions depending on access to medical care. Unlike in classic Turner syndrome, an association with advanced maternal age is not clear in the mosaic form. In Korea, it is registered and managed under rare disease Special Copayment Reduction V021 (Q96 group).
The pathophysiology of mosaic Turner syndrome is determined by the types of tissue in which the 45,X cell line is present and its proportion. The core pathogenic features are reduced ovarian function, growth impairment and organ malformations (cardiovascular, renal).
In terms of ovarian development, because 45,X cells lack a second X (or Y), meiosis of germ cells (oogonia) proceeds abnormally and early follicle loss occurs. Normal females form up to about 7 million primordial follicles during fetal life, but the higher the proportion of 45,X cells, the more follicle loss accelerates from fetal life, and the ovaries are replaced by streak gonads at birth or before puberty. In mosaic forms in which the 46,XX cell line is sufficiently preserved, some follicles are maintained, leaving the possibility of spontaneous puberty and pregnancy.
Growth impairment is mainly due to SHOX gene haploinsufficiency. SHOX is located in the pseudoautosomal region (PAR1) of Xp22.33 and Yp and escapes X inactivation; the more 45,X cells there are, the more only one copy is expressed and long bone growth is suppressed. Cardiovascular malformations (bicuspid aortic valve, coarctation of the aorta, aortic dilation) originate from abnormal vascular development due to impaired fetal lymphatic flow, and in the mosaic form their frequency decreases as the proportion of 45,X cells decreases. Renal abnormalities are also associated with an increased proportion of local 45,X cells during fetal life.
In the 45,X/46,XY mosaic form, the direction of gonadal development is determined by the proportion of SRY-positive cells in gonadal tissue. If the proportion is high, development proceeds toward a male phenotype with testicular development and testosterone production; if low, streak gonads or mixed gonads form. Because the TSPY1 gene in the GBY region increases the risk of gonadoblastoma, clinical attention is needed.
The clinical symptoms of mosaic Turner syndrome (Q96.3) are generally milder than those of the classic form (Q96.0, 45,X), and phenotypic variation is very large. Some patients show a nearly normal phenotype.
Short stature is the most common symptom, with a mean adult height of about 143–150 cm without treatment. Growth velocity and final height vary with the degree of SHOX haploinsufficiency. Hypogonadism and ovarian failure are less severe in the 45,X/46,XX mosaic form than in the classic form, and in some, spontaneous puberty begins and menarche occurs. However, premature ovarian insufficiency (POI) may progress in the 20s–30s, with symptoms of estrogen deficiency (hot flashes, osteoporosis, increased cardiovascular risk).
Primary amenorrhea occurs when ovarian function is insufficient and is seen in about 30–50% of the 45,X/46,XX mosaic form. Secondary amenorrhea also occurs as follicle loss progresses. The typical Turner physical features of webbed neck, shield chest, cubitus valgus and lymphedema are less frequent and less severe in the mosaic form. Cognitive function is generally normal, but reduced visuospatial processing ability and attention deficits are reported.
In the 45,X/46,XY mosaic form, phenotypic females may have incomplete feminizing breast development and external genital abnormalities (clitoromegaly, etc.). In phenotypic males or those with ambiguous genitalia, gonadal dysgenesis, hypospadias and cryptorchidism are the main symptoms. Hypothyroidism due to autoimmune thyroiditis, prediabetes, hearing loss due to otitis media, strabismus and others may also occur.
Objective signs by organ system are as follows.
Bicuspid aortic valve is observed in about 15–30% of all Turner syndrome and is also present in the mosaic form. Coarctation of the aorta is reported in about 7–14%. Even without structural malformations, the risk of aortic dilation and dissection is increased, so regular measurement of aortic diameter with cardiac MRI is recommended. Hypertension also occurs independently of renal abnormalities or coarctation of the aorta.
Horseshoe kidney, duplicated collecting systems and ureteral abnormalities are found in about 20–30% of all Turner syndrome, with lower frequency in the mosaic form. They can cause recurrent urinary tract infections and hypertension.
Autoimmune thyroiditis (Hashimoto thyroiditis) occurs in about 15–30%. The risk of type 2 diabetes and insulin resistance is increased, requiring monitoring for metabolic syndrome. Osteopenia and osteoporosis progress in adulthood due to estrogen deficiency.
Gonadoblastoma arises within the gonad, progresses asymptomatically and can transform into malignant dysgerminoma. Confirmation of the anatomic location and histologic characteristics of the gonads is important.
Sensorineural and conductive hearing loss may occur. Strabismus, amblyopia and color vision deficiency occur at a higher frequency than in the general population.
Because mosaic Turner syndrome has a mild phenotype, screening is difficult. Performing the appropriate tests at each stage of life is key to early diagnosis.
Cell-free fetal DNA (cfDNA, NIPT) is used to screen for sex chromosome aneuploidies. Sensitivity for screening X chromosome monosomy is high, but false negatives can occur in the mosaic form when the proportion of 45,X cells is low. False positives due to placental mosaicism also occur, so positive results must be verified by invasive confirmation (amniocentesis or chorionic villus sampling). When fetal ultrasound shows cystic hygroma, coarctation of the aorta, horseshoe kidney or hydrops fetalis, a sex chromosome abnormality is suspected.
Karyotype analysis is considered in the following situations: (1) unexplained growth delay, (2) delayed puberty (no breast development by age 13 or older), (3) primary amenorrhea (no menarche by age 15 or older), (4) unexplained aortic malformation or horseshoe kidney, (5) lymphedema of the hands and feet in the neonatal period, (6) presence of Turner physical features, even mild ones.
Sex chromosome aneuploidy is sometimes found during infertility evaluation or assessment of premature ovarian insufficiency (POI). Turner syndrome (classic or mosaic) is confirmed in about 2–5% of adult women with primary ovarian insufficiency.
Confirmation is by peripheral blood G-banded karyotype analysis, and counting at least 30 mitotic cells is the recommended standard. Because low-level mosaicism (<10%) can be missed by standard karyotype analysis, additional techniques are needed.
Biochemical tests: FSH, LH, estradiol (E2) and AMH (anti-Müllerian hormone) to assess ovarian reserve. Growth hormone stimulation test, TSH, fasting glucose, indices of insulin resistance. Echocardiography and cardiac MRI (aortic diameter measurement), renal ultrasound, hearing tests and bone densitometry (DEXA) are performed at diagnosis.
An individualized multidisciplinary approach according to the degree of phenotype is needed.
Recombinant human growth hormone (rhGH) is used in patients with short stature to improve final height. It is recommended by the Korean Society of Pediatric Endocrinology and international guidelines and is usually given from age 2 or older until growth plate fusion. Monitoring for increased insulin resistance is needed.
When ovarian function is not sufficiently preserved and spontaneous puberty does not begin, puberty is induced from age 11–12 with low-dose estrogen (transdermal estradiol preferred). The dose is increased gradually over 2–3 years, followed by addition of a progestin. In adulthood, hormone replacement therapy is maintained until age 50.
When the presence of Y chromosome material is confirmed, prophylactic gonadectomy (laparoscopic) is the traditional guideline. Because some recent guidelines present regular ultrasound surveillance as an option, shared decision-making reflecting the patient's situation and preferences is recommended.
Drug treatment of hypertension (ACE inhibitor or ARB preferred), levothyroxine replacement for hypothyroidism, and management of prediabetes and metabolic syndrome. If a bicuspid aortic valve or coarctation of the aorta is present, consultation with cardiology and cardiovascular surgery is essential. Oocyte cryopreservation is carried out after early counseling.
The prognosis of mosaic Turner syndrome is generally better than that of the classic form. With appropriate medical management, life expectancy is close to normal. The main prognostic determinant is the presence and severity of cardiovascular malformations, and aortic dissection and rupture are the main causes of Turner syndrome-related death. This also applies to the mosaic form when a bicuspid aortic valve or aortic dilation is present.
In terms of reproductive function, spontaneous pregnancy is possible in some with the 45,X/46,XX mosaic form. However, because the risks of progression of premature ovarian insufficiency and fetal chromosomal abnormalities (particularly 45,X fetuses, spontaneous miscarriage) increase in pregnancy, genetic counseling is essential. AMH levels and ovarian reserve are monitored regularly, and early oocyte cryopreservation is discussed. Cognitive function and educational attainment are generally normal, but deficits in visuospatial processing, mathematical ability and attention are reported in some. Psychosocial support is important for improving quality of life.
In the 45,X/46,XY type, the risk of gonadoblastoma is eliminated after prophylactic gonadectomy, but because the state of estrogen deficiency becomes permanent, hormone replacement becomes even more important. When the surveillance pathway is chosen, regular ultrasound and AFP and β-hCG monitoring are needed.
Because mosaic Turner syndrome arises from sporadic errors in the process of mitosis, primary prevention is difficult. However, prevention of complications and improvement of quality of life are possible through a systematic approach.
When a woman with Turner syndrome plans a pregnancy, genetic counseling is provided on the possibility of spontaneous pregnancy and the risk of fetal chromosomal abnormalities (increased by about 5–10%). cfDNA, amniocentesis and chorionic villus sampling are used for prenatal diagnosis, and in assisted reproduction, embryos with a normal karyotype are selected by preimplantation genetic testing (PGT-A).
To prevent cardiovascular complications, cardiac MRI is performed at diagnosis and at 5–10-year intervals, and blood pressure is strictly managed. Thyroid function, glucose metabolism and bone density are assessed regularly. Estrogen replacement therapy prevents osteoporosis, cardiovascular risk and cognitive decline. Continued follow-up into adulthood through a specialized Turner syndrome multidisciplinary clinic is recommended.
At diagnosis, patients and families are thoroughly educated about the nature of the disease, the need for long-term follow-up, reproductive possibilities and the importance of hormone therapy. Psychosocial support through links with patient organizations is also recommended as part of preventive management.